Literature DB >> 24310524

Risk factors for relapse and surgery rate in children with Crohn's disease.

Iva Hojsak1, Ana Močić Pavić, Zrinjka Mišak, Sanja Kolaček.   

Abstract

UNLABELLED: The aim of this study was to evaluate risk factors associated with the relapse rate in the first year and the need for surgery in children with Crohn's disease (CD). Data of all children (n = 74) diagnosed with CD from January 2004 to June 2011 were retrospectively analyzed. Multivariate Cox proportional hazards regression model was used to assess whether important clinical variables at diagnosis (age, presence of perianal disease, first induction therapy, first maintenance therapy, levels of Pediatric CD Activity Index (PCDAI), C-reactive protein (CRP), and standard deviation score (SDS) for height for weight) were associated with the risk of clinical recurrence in the first year and need for surgery during follow-up. Relapse occurred in 36 (48.6 %) patients in the first year from diagnosis. The only significant parameter associated with negative risk of relapse in the first year was exclusive enteral nutrition (EEN) used as induction therapy (hazard ratio (HR) 0.469, 95 % confidence interval (CI) 0.232-0.948). EEN induced remission in 84.2 % of patients. The only risk associated with EEN treatment failure was the involvement of the upper gastrointestinal tract. During the follow-up, 25 (33.7 %) patients underwent surgery. The multivariate Cox regression model failed to recognize significant risk factor for surgery.
CONCLUSION: This study underlines the importance of early EEN in the treatment of CD; it is not only efficacious in the remission induction but could also prevent relapse in the first year.

Entities:  

Mesh:

Year:  2013        PMID: 24310524     DOI: 10.1007/s00431-013-2230-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  33 in total

1.  Longer-term outcomes of nutritional management of Crohn's disease in children.

Authors:  B Lambert; D A Lemberg; S T Leach; A S Day
Journal:  Dig Dis Sci       Date:  2012-06-02       Impact factor: 3.199

2.  Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.

Authors:  S Kugathasan; S L Werlin; A Martinez; M T Rivera; J B Heikenen; D G Binion
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

3.  Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial.

Authors:  Osvaldo Borrelli; Letizia Cordischi; Manuela Cirulli; Massimiliano Paganelli; Valeria Labalestra; Stefania Uccini; Paolo M Russo; Salvatore Cucchiara
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-06       Impact factor: 11.382

4.  Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria.

Authors: 
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-07       Impact factor: 2.839

5.  Long-term outcome of nutritional therapy in paediatric Crohn's disease.

Authors:  C Knight; Wael El-Matary; Christine Spray; Bhupinder K Sandhu
Journal:  Clin Nutr       Date:  2005-10       Impact factor: 7.324

6.  Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.

Authors:  Andrew S Day; Kylie E Whitten; Daniel A Lemberg; Cathy Clarkson; Maribel Vitug-Sales; Reuben Jackson; Tim D Bohane
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

7.  Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease.

Authors:  R M Beattie; E J Schiffrin; A Donnet-Hughes; A C Huggett; P Domizio; T T MacDonald; J A Walker-Smith
Journal:  Aliment Pharmacol Ther       Date:  1994-12       Impact factor: 8.171

8.  Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.

Authors:  Jaya Punati; James Markowitz; Trudy Lerer; Jeffrey Hyams; Subra Kugathasan; Anne Griffiths; Anthony Otley; Joel Rosh; Marian Pfefferkorn; David Mack; Jonathan Evans; Athos Bousvaros; M Susan Moyer; Robert Wyllie; Maria Oliva-Hemker; Adam Mezoff; Neal Leleiko; David Keljo; Wallace Crandall
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

9.  Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.

Authors:  Michael C Stephens; Melissa A Shepanski; Petar Mamula; Jonathan E Markowitz; Kurt A Brown; Robert N Baldassano
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

10.  Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry.

Authors:  Charlotte I de Bie; Anders Paerregaard; Sanja Kolacek; Frank M Ruemmele; Sibylle Koletzko; John M E Fell; Johanna C Escher
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

View more
  8 in total

Review 1.  Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.

Authors:  A Swaminath; A Feathers; A N Ananthakrishnan; L Falzon; S Li Ferry
Journal:  Aliment Pharmacol Ther       Date:  2017-08-16       Impact factor: 8.171

2.  The SES-CD Could Be a Predictor of Short- and Long-Term Mucosal Healing After Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients.

Authors:  Wenjuan Tang; Wenhui Hu; Peng Shi; Ziqing Ye; Jie Wu; Ye Zhang; Yuhuan Wang; Ying Huang
Journal:  Front Pediatr       Date:  2022-05-18       Impact factor: 3.569

Review 3.  Diet and nutrition in the management of inflammatory bowel disease.

Authors:  Pabitra Sahu; Saurabh Kedia; Vineet Ahuja; Rakesh K Tandon
Journal:  Indian J Gastroenterol       Date:  2021-05-26

Review 4.  ORAL AND ENTERAL NUTRITION THERAPY IN INFLAMMATORY BOWEL DISEASES AMONG THE PEDIATRIC POPULATION: A LITERATURE REVIEW.

Authors:  Gabriela Neves de Souza; Patrícia Ferrante Draghi; Glauce Hiromi Yonamine
Journal:  Rev Paul Pediatr       Date:  2020-06-05

5.  Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP.

Authors:  Melinda Moriczi; Gemma Pujol-Muncunill; Rafael Martín-Masot; Santiago Jiménez Treviño; Oscar Segarra Cantón; Carlos Ochoa Sangrador; Luis Peña Quintana; Daniel González Santana; Alejandro Rodríguez Martínez; Antonio Rosell Camps; Honorio Armas; Josefa Barrio; Rafael González de Caldas; Mónica Rodríguez Salas; Elena Balmaseda Serrano; Ester Donat Aliaga; Andrés Bodas Pinedo; Esther Vaquero Sosa; Raquel Vecino López; Alfonso Solar Boga; Ana Moreno Álvarez; César Sánchez Sánchez; Mar Tolín Hernani; Carolina Gutiérrez Junquera; Nazareth Martinón Torres; María Rosaura Leis Trabazo; Francisco Javier Eizaguirre; Mónica García Peris; Enrique Medina Benítez; Beatriz Fernández Caamaño; Ana María Vegas Álvarez; Laura Crespo Valderrábano; Carmen Alonso Vicente; Javier Rubio Santiago; Rafael Galera-Martínez; Ruth García-Romero; Ignacio Ros Arnal; Santiago Fernández Cebrián; Helena Lorenzo Garrido; Javier Francisco Viada Bris; Marta Velasco Rodríguez-Belvis; Juan Manuel Bartolomé Porro; Miriam Blanco Rodríguez; Patricia Barros García; Gonzalo Botija; Francisco José Chicano Marín; Enrique La Orden Izquierdo; Elena Crehuá-Gaudiza; Víctor Manuel Navas-López; Javier Martín-de-Carpi
Journal:  Nutrients       Date:  2020-04-07       Impact factor: 5.717

6.  A Case of a Two-Month-Old Boy Diagnosed with Infantile Crohn's Disease Based on an Atypical Perianal Lesion.

Authors:  Kengo Nakaya; Yasushi Iinuma; Yutaka Hirayama; Yu Sugai; Shotaro Taki
Journal:  Case Rep Pediatr       Date:  2020-12-09

Review 7.  EEN Yesterday and Today … CDED Today and Tomorrow.

Authors:  Marta Herrador-López; Rafael Martín-Masot; Víctor Manuel Navas-López
Journal:  Nutrients       Date:  2020-12-10       Impact factor: 5.717

8.  Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients.

Authors:  Eun Sil Kim; Yiyoung Kwon; Yon Ho Choe; Mi Jin Kim
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.